CN102858343B - 用于治疗或预防激素变化症状的方法和组合物 - Google Patents

用于治疗或预防激素变化症状的方法和组合物 Download PDF

Info

Publication number
CN102858343B
CN102858343B CN201180020427.2A CN201180020427A CN102858343B CN 102858343 B CN102858343 B CN 102858343B CN 201180020427 A CN201180020427 A CN 201180020427A CN 102858343 B CN102858343 B CN 102858343B
Authority
CN
China
Prior art keywords
dextromethorphan
symptoms
hot flashes
receptors
subtype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180020427.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102858343A (zh
Inventor
小乔治·E·罗伊斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN102858343A publication Critical patent/CN102858343A/zh
Application granted granted Critical
Publication of CN102858343B publication Critical patent/CN102858343B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201180020427.2A 2010-03-02 2011-03-01 用于治疗或预防激素变化症状的方法和组合物 Active CN102858343B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30963810P 2010-03-02 2010-03-02
US61/309,638 2010-03-02
PCT/US2011/026650 WO2011109367A2 (en) 2010-03-02 2011-03-01 Methods and compositions for treating or preventing symptoms of hormonal variations

Publications (2)

Publication Number Publication Date
CN102858343A CN102858343A (zh) 2013-01-02
CN102858343B true CN102858343B (zh) 2015-11-25

Family

ID=44531862

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180020427.2A Active CN102858343B (zh) 2010-03-02 2011-03-01 用于治疗或预防激素变化症状的方法和组合物

Country Status (12)

Country Link
US (1) US20110218213A1 (enExample)
EP (1) EP2542241B1 (enExample)
JP (1) JP5839362B2 (enExample)
CN (1) CN102858343B (enExample)
AU (3) AU2011223807B2 (enExample)
BR (1) BR112012022052B1 (enExample)
CA (1) CA2828041C (enExample)
EA (1) EA027350B1 (enExample)
ES (1) ES2574210T3 (enExample)
IL (2) IL221706A (enExample)
PL (1) PL2542241T3 (enExample)
WO (1) WO2011109367A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9616123B1 (en) * 2012-03-05 2017-04-11 Robert L. Knobler Method and compound for treatment of menopausal symptoms
CN107249615B (zh) * 2015-04-07 2021-02-05 株式会社明治 潮热抑制剂
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
WO2020219270A1 (en) * 2019-04-22 2020-10-29 Knobler Robert L Non-hormonal treatment of hot flashes
WO2021108801A2 (en) * 2019-11-15 2021-06-03 Consegna Pharma, Inc. Long acting nmda antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090111846A1 (en) * 2006-02-03 2009-04-30 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disorders
CN101588804A (zh) * 2006-12-13 2009-11-25 永信药品工业股份有限公司 治疗或防治激素变异症状的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
EP2275089A1 (en) * 1993-11-19 2011-01-19 Alkermes Controlled Therapeutics, Inc. Preparation of biodegradable microparticles containing a biologically active agent
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
DE60034344T2 (de) * 1999-07-22 2008-01-10 University Of Rochester Methode zur behandlung der symptome hormoneller veränderungen, einschliesslich hitzewallungen
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6569471B2 (en) * 2000-09-01 2003-05-27 Natumin Pharma Ab Method for the treatment of symptoms related to normal hormonal variations in women
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US20040259850A1 (en) * 2001-10-31 2004-12-23 Alves Stephen E. Method for treating or preventing symptoms of hormonal variation including hot flashes
UA81423C2 (en) * 2002-08-15 2008-01-10 PRODUCT CONTAINING SRI AND AGONIST OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
HUP0303313A2 (hu) * 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
JP2007537232A (ja) * 2004-05-11 2007-12-20 ファイザー・プロダクツ・インク 非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ
WO2005120523A1 (en) * 2004-06-04 2005-12-22 Mood Management Sciences, Llc Methods and compositions for treating mood disorder
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
EP1898915A4 (en) * 2005-07-06 2009-01-21 Sepracor Inc COMBINATIONS OF ESZOPICLON AND ANTIDEPRESSIVE
MX2008007589A (es) * 2005-12-13 2009-01-27 Trinity Lab Inc Un metodo para tratar eyaculacion prematura en seres humanos.
ES2423485T3 (es) * 2007-03-19 2013-09-20 Acadia Pharmaceuticals Inc. Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos
US9216206B2 (en) * 2008-07-22 2015-12-22 Menogenix, Inc. Methods of treating symptoms associated with menopause and hormonal variations with G-CSF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090111846A1 (en) * 2006-02-03 2009-04-30 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disorders
CN101588804A (zh) * 2006-12-13 2009-11-25 永信药品工业股份有限公司 治疗或防治激素变异症状的方法

Also Published As

Publication number Publication date
EP2542241B1 (en) 2016-04-27
PL2542241T3 (pl) 2016-12-30
US20110218213A1 (en) 2011-09-08
EP2542241A2 (en) 2013-01-09
IL253853B (en) 2019-05-30
AU2011223807B2 (en) 2016-05-12
IL253853A0 (en) 2017-09-28
CA2828041C (en) 2018-04-17
AU2016213776B2 (en) 2018-04-12
IL221706A (en) 2017-08-31
AU2016213776A1 (en) 2016-09-01
WO2011109367A2 (en) 2011-09-09
ES2574210T3 (es) 2016-06-15
EA027350B1 (ru) 2017-07-31
AU2018205147A1 (en) 2018-08-02
AU2011223807A1 (en) 2012-10-18
JP2013521297A (ja) 2013-06-10
WO2011109367A3 (en) 2011-12-29
CN102858343A (zh) 2013-01-02
WO2011109367A4 (en) 2012-02-23
BR112012022052A2 (pt) 2020-07-07
EA201290851A1 (ru) 2013-04-30
BR112012022052B1 (pt) 2021-06-29
JP5839362B2 (ja) 2016-01-06
CA2828041A1 (en) 2011-09-09
EP2542241A4 (en) 2013-11-06

Similar Documents

Publication Publication Date Title
US8461102B2 (en) Methods and compositions for treating and preventing symptoms of hormonal variations
US8420624B2 (en) Methods for treating or preventing symptoms of hormonal variations
AU2016213776B2 (en) Methods and compositions for treating or preventing symptoms of hormonal variations
CN101896174B (zh) 用于治疗代谢综合征的珠氯米芬
CN101588804B (zh) 治疗或防治激素变异症状的方法
US20110124617A1 (en) Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent
EA003142B1 (ru) Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения
CN1674880A (zh) 用于治疗体温调节机能障碍的5HT2a受体的激动作用
US20040180879A1 (en) Novel method of treating vasomotor symptoms
EP2089022A2 (en) Composition containing a mixture of antidepressants for treating premature ejaculation
Stearns Management of hot flashes in breast cancer survivors and men with prostate cancer
Leong et al. Treating recurrent postmenopausal vasomotor symptoms in a patient with a positive family history for breast cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant